Antares Pharma Inc. Risk Report

⚖️ Legal & Regulatory

Antares Pharma has recently faced significant legal challenges which may impact its financial stability and operations due to pending lawsuits and regulatory matters. Notably, firms are encouraging investors to take action over financial losses possibly tied to the company's operations. Compliance with regulatory standards remains a concern that needs to be carefully managed.

• On 🗓 June 4, 2025, Faruqi & Faruqi, LLP called for Antares Pharma investors who suffered losses exceeding $50,000 to contact the firm, suggesting potential legal action against the company.

📜 Innovation & R&D

Antares Pharma has continued to innovate, notably achieving milestones in the development of novel drugs and treatments. The company has been active in expanding its product pipelines, which signals a commitment to research and development as a key part of its operational strategy.

• Antares therapeutics launched with $177 million funding on 🗓 June 10, 2025, aiming to develop first-in-class precision medicines for cancer and other serious diseases.
• The company received FDA fast track designation for ATRS-1902 for adrenal crisis rescue on 🗓 January 18, 2022, highlighting its commitment to developing advanced therapeutic solutions.
• On 🗓 March 29, 2022, Antares and Lipocine expanded their testosterone therapy offerings with FDA approval for a new oral medication.